Literature DB >> 27499541

Basic science for the clinician: Mechanisms of sublingual and subcutaneous immunotherapy.

Monica G Lawrence1, John W Steinke2, Larry Borish3.   

Abstract

OBJECTIVE: To discuss the general immunologic changes that occur during immunotherapy, focusing on the differences between subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT). DATA SOURCES: PubMed literature review. STUDY SELECTIONS: Articles pertaining to SCIT and SLIT, with specific emphasis on those that included immune mechanistic studies.
RESULTS: Both SCIT and SLIT are characterized by the induction of regulatory B and T cells, decreased allergen-specific T-cell proliferation, a shift from a TH2 to TH1 cytokine milieu and from an IgE to an IgG4/IgA antibody response. These changes are accompanied by clinical improvement in symptoms.
CONCLUSION: Immunotherapy using allergen extracts administered via both subcutaneous and sublingual approaches have demonstrated efficacy in the treatment of allergic rhinoconjunctivitis and other allergic conditions. There are subtle differences between the approaches, and understanding these differences may help clinicians select a preferred route of therapy for particular patients or allergens, depending on the immune response that is being targeted.
Copyright © 2016 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27499541      PMCID: PMC4978173          DOI: 10.1016/j.anai.2016.06.027

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  68 in total

1.  Clinical and cytokine responses to house dust mite sublingual immunotherapy.

Authors:  Paul C Potter; Sheila Baker; Bartha Fenemore; Barbara Nurse
Journal:  Ann Allergy Asthma Immunol       Date:  2015-02-03       Impact factor: 6.347

2.  Mechanisms of immunotherapy and surrogate markers.

Authors:  S Till
Journal:  Allergy       Date:  2011-07       Impact factor: 13.146

3.  Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies.

Authors:  Louisa K James; Mohamed H Shamji; Samantha M Walker; Duncan R Wilson; Petra A Wachholz; James N Francis; Mikila R Jacobson; Ian Kimber; Stephen J Till; Stephen R Durham
Journal:  J Allergy Clin Immunol       Date:  2011-02       Impact factor: 10.793

Review 4.  Allergen immunotherapy.

Authors:  Anthony J Frew
Journal:  J Allergy Clin Immunol       Date:  2010-02       Impact factor: 10.793

Review 5.  Antigen-specific tolerance in immunotherapy of Th2-associated allergic diseases.

Authors:  Charles B Smarr; Paul J Bryce; Stephen D Miller
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

6.  Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom.

Authors:  U Müller; C A Akdis; M Fricker; M Akdis; T Blesken; F Bettens; K Blaser
Journal:  J Allergy Clin Immunol       Date:  1998-06       Impact factor: 10.793

7.  Effects of sublingual immunotherapy for Dermatophagoides farinae on Th17 cells and CD4(+) CD25(+) regulatory T cells in peripheral blood of children with allergic asthma.

Authors:  Man Tian; Yu Wang; Yueqing Lu; Yan-he Jiang; De-yu Zhao
Journal:  Int Forum Allergy Rhinol       Date:  2014-03-03       Impact factor: 3.858

8.  Intralymphatic injections as a new administration route for allergen-specific immunotherapy.

Authors:  Julia M Martínez-Gómez; Pål Johansen; Iris Erdmann; Gabriela Senti; Reto Crameri; Thomas M Kündig
Journal:  Int Arch Allergy Immunol       Date:  2009-04-02       Impact factor: 2.749

9.  Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis.

Authors:  Alain Didier; Hans-Jörgen Malling; Margitta Worm; Friedrich Horak; Siegfried Jäger; Armelle Montagut; Claude André; Olivier de Beaumont; Michel Melac
Journal:  J Allergy Clin Immunol       Date:  2007-11-01       Impact factor: 10.793

10.  In vivo and in vitro studies of Th17 response to specific immunotherapy in house dust mite-induced allergic rhinitis patients.

Authors:  Chun Wei Li; Han Gui Lu; De Hua Chen; Zhi Bin Lin; De Yun Wang; Tian Ying Li
Journal:  PLoS One       Date:  2014-03-19       Impact factor: 3.240

View more
  6 in total

Review 1.  Could This Be IT? Epicutaneous, Sublingual, and Subcutaneous Immunotherapy for the Treatment of Food Allergies.

Authors:  Mary Grace Baker; Julie Wang
Journal:  Curr Allergy Asthma Rep       Date:  2019-11-25       Impact factor: 4.806

2.  Circulating C-X-C Motif Ligand 13 as a Biomarker for Early Predicting Efficacy of Subcutaneous Immunotherapy in Children With Chronic Allergic Rhinitis.

Authors:  Shenghao Cheng; Sihui Wen; Shaobing Xie; Caixia Zhang; Hua Zhang; Kelei Gao; Ruohao Fan; Zhihai Xie; Weihong Jiang
Journal:  Front Pediatr       Date:  2022-05-04       Impact factor: 3.418

Review 3.  Advancement of antigen-specific immunotherapy: knowledge transfer between allergy and autoimmunity.

Authors:  Naomi Richardson; David Cameron Wraith
Journal:  Immunother Adv       Date:  2021-05-22

Review 4.  Immune mechanisms induced by sublingual immunotherapy in allergic respiratory diseases.

Authors:  Umut Gazi; Nerin Nadir Bahceciler
Journal:  Clin Exp Immunol       Date:  2022-09-29       Impact factor: 5.732

5.  Subcutaneous birch pollen allergen immunotherapy with a depigmented polymerized extract shows only sustained and long-term efficacy in a subgroup of monosensitized adults and adolescents with allergic rhinitis.

Authors:  Natalija Novak; Margitta Worm; Petra Staubach; Marek Jutel; Angelika Sager; Oliver Pfaar
Journal:  Clin Transl Allergy       Date:  2022-10-05       Impact factor: 5.657

Review 6.  Go With Your Gut: The Shaping of T-Cell Response by Gut Microbiota in Allergic Asthma.

Authors:  Alessandro Di Gangi; Maria Elisa Di Cicco; Pasquale Comberiati; Diego G Peroni
Journal:  Front Immunol       Date:  2020-07-14       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.